

4th International Conference and Exhibition on **Pharmacovigilance & Clinical Trials** August 10-12, 2015 London, UK

Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population

Maryam Payan, Mohammad Reza Rouini, Nader Tajik, Mohammad Hossein Ghahremani and Reza Tahvilian
Tehran University of Medical Sciences, Iran

Background: Polymorphism of *CYP2C19* gene is one of the important factors in pharmacokinetics of *CYP2C19* substrates. Omeprazole is a proton pump inhibitor which is mainly metabolized by cytochrome P450 2C19 (*CYP2C19*). The aim of present study was to assess omeprazole hydroxylation index as a measure of *CYP2C19* activity considering new variant allele (*CYP2C19**17) in Iranian population and also to see if this activity is sex dependent.

Methods: One hundred and eighty healthy unrelated Iranian individuals attended in this study. Blood samples for genotyping and phenotyping were collected 3 hours after administration of 20 mg omeprazole orally. Genotyping of 2C19 variant alleles *2, *3 and *17 was performed by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and semi-nested PCR methods. Plasma concentrations of omeprazole and hydroxyomeprazole were determined by high performance liquid chromatography (HPLC) technique and hydroxylation index (HI) (omeprazole/ hydroxyomeprazole) was calculated.

Results: The *CYP2C19**17 was the most common variant allele in the studied population (21.6%). Genotype frequencies of *CYP2C19**17*17, *1*17, and *2*17 were 5.5%, 28.8% and 3.3% respectively. The lowest and the highest median omeprazole HI was observed in *17*17 and *2*2 genotypes respectively (0.36 vs. 13.09). The median HI of omeprazole in subjects homozygous for *CYP2C19**1 was 2.16-fold higher than individuals homozygous for *CYP2C19**17 ($P<0.001$) and the median HI of *CYP2C19**1*17 genotype was 1.98-fold higher than *CYP2C19* *17*17 subjects ($P<0.001$). However, subjects with *CYP2C19**2*17 (median HI: 1.74) and *CYP2C19**1*2 (median HI: 1.98) genotypes and also *CYP2C19**1*17 (median HI: 0.71) and *CYP2C19**1*1 (mean HI: 0.78) did not show any significantly different enzyme activity. In addition, no statistically significant difference was found between women and men in distribution of *CYP2C19* genotypes. Furthermore, the hydroxylation index of Omeprazole was not different between women and men in the studied population.

Conclusion: Our data point out the importance of *CYP2C19**2 and *CYP2C19**17 variant alleles in metabolism of omeprazole and therefore *CYP2C19* activity. Regarding the high frequency of *CYP2C19**17 in Iranian population, the importance of this new variant allele in metabolism of *CYP2C19* substrates shall be considered.

payan@razi.tums.ac.ir

Notes: